{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/WAC"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"WAC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WAC\",,,,,undefined,":{"symbol":"WAC","market":"US","secType":"STK","nameCN":"Walter Investment Management","latestPrice":0.6,"timestamp":1518210000000,"preClose":0.6674,"halted":4,"volume":641696,"delay":0,"floatShares":18492716,"shares":36542000,"eps":-14.77,"marketStatus":"Delisted","change":-0.0674,"latestTime":"05-02 09:05:17 EDT","open":0.66,"high":0.66,"low":0.56,"amount":385017.6,"amplitude":0.149835,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-14.77,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746192600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":0.6674,"volumeRatio":2.083722},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WAC\",,,,,undefined,":{"symbol":"WAC","floatShares":18492716,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.083722,"shares":36542000,"dividePrice":0,"high":0.66,"amplitude":0.149835,"preClose":0.6674,"low":0.56,"week52Low":0.302,"pbRate":"-0.09","week52High":4.25,"institutionHeld":1.0028,"latestPrice":0.6,"eps":-14.77,"divideRate":0,"volume":641696,"delay":0,"ttmEps":-14.77,"open":0.66},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/WAC\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"WAC\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531051887","title":"ABEO: Zevaskyn™ Approved by FDA; Raising Valuation to $11…","url":"https://stock-news.laohu8.com/highlight/detail?id=2531051887","media":"Zacks Small Cap Research","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531051887?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:05","pubTimestamp":1746007500,"startTime":"0","endTime":"0","summary":"On April 29, 2025, Abeona Therapeutics, Inc.  announced that the U.S. Food and Drug Administration  has approved Zevaskyn  for the treatment of wounds in adults and children with recessive dystrophic epidermolysis bullosa . The company indicated that the commercial launch will commence in the third quarter of 2025. Zevaskyn will have a wholesale acquisition cost  of $3.1 million, which is significantly more than what we had been modeling . Management guided that between 10-14 patients are expected to be treated, and revenue recognized from those treatments, this year. Manufacturing capacity is expected to be able to handle up to six treatments per month by the end of 2025 and up to 10 treatments per month by mid-2026. The company reiterated that the total addressable market for Zevaskyn is approximately 750 patients in the U.S., with an estimated two procedures necessary for patients to cover most of their wounds. At the proposed WAC this represents a >$4 billion market opportunity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abeo-zevaskyn-approved-fda-raising-100500085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["WAC","ABEO","BK4139"],"gpt_icon":0},{"id":"2525017329","title":"Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2525017329","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525017329?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"EPYSQLI  is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive. EPYSQLI will be available at a 30% discount of the Wholesale Acquisition Cost  of the reference product, Soliris , making it one of the greatest cost-saving biosimilars to Soliris in the U.S.Teva and Samsung Bioepis entered into a strategic partnership in January 2025 for the commercialization of EPYSQLI in the U.S., furthering both companies’ commitment to bring more accessible treatment options to rare disease patients","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/teva-samsung-bioepis-announce-biosimilar-120000664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4584","UBCP","BK4596","PP","TEVA","BK4585","BK4211","WAC","BK4007","BK4557","BK4559","BK4588","BK4566"],"gpt_icon":0},{"id":"2517157041","title":"Velocity Financial, Inc. Reports Fourth Quarter and Full Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2517157041","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517157041?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:10","pubTimestamp":1741295400,"startTime":"0","endTime":"0","summary":"Net income of $20.6 million, up 18.6% from $17.4 million for 4Q23. Diluted EPS of $0.57, up $0.07 from $0.50 per share for 4Q23. Core net income of $21.8 million, an increase of 34.6% from $16.2 million for 4Q23. Core diluted EPS of $0.60, up from $0.46 per share for 4Q23. Loan production of $563.5 million in UPB, an 18.2% and 60.0% increase from 3Q24 and 4Q23, respectively. Year-to-date 2025 loan production through February of $429.4 million. Nonperforming loans  as a percentage of Held for Investment  loans was 10.7%, up slightly from 10.6% as of September 30, 2024, and 9.7% as of December 31, 2023, respectively. Resolutions of NPL and real estate owned  totaled $79.4 million in UPB. Realized gains of $5.6 million or 107.0% of UPB resolved. Completed the VCC 2024-5 and VCC 2024-6 securitizations totaling $292.9 million and 293.9 million, respectively, of securities issued. Liquidity of $95.9 million and total available warehouse line capacity of $435.0 million as of December 31, 2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/velocity-financial-inc-reports-fourth-211000023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4229","BK4195","BK4139","UPB","WAC","NIM","VEL"],"gpt_icon":0},{"id":"2514896706","title":"Press Release: Mesoblast Sets Ryoncil(R) Price Based on Economic Value of Treatment With Planned Product Availability This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2514896706","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514896706?lang=en_us&edition=fundamental","pubTime":"2025-02-27 06:30","pubTimestamp":1740609000,"startTime":"0","endTime":"0","summary":"Mesoblast Sets Ryoncil Price Based on Economic Value of Treatment With Planned Product Availability This Quarter. Financial Results and Operational Update for Half-Year Ended December 31, 2024. NEW YORK, Feb. 26, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2024,\"Our FDA approved product Ryoncil will be available in the coming weeks to the children with SR-aGvHD in need of life-saving therapy,\" said Dr. Silviu Itescu, Chief Executive of Mesoblast. \"The treatment has delivered long-term survival outcomes in these very high-risk patients and we are pleased with the benefits and value that this treatment brings to patients and their healthcare providers at specialized transplant centers across the U.S.\". Ryoncil  U.S. Launch for Steroid-Refractory Acute Graft Versus Host Disease. FDA approved Ryoncil as the first and only therapy for pediat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","R","BK7508","BK4232","BK7501","BK4022","TM","BK4183","DDD","BK4170","BK4575","BK4551","BK4546","IBD","03160","WAC","MMAT","BK7067","BK4604","BK4116","BK4588","BK4150","ORR","MSC","BK4099","BK4555","BK4161","CD","BK4139","MSB.AU","BK4585","ODD","MESO"],"gpt_icon":1}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/WAC\",params:#limit:5,,,undefined,":[{"date":"2018-02-12","symbol":"WAC","newSymbol":"DHCP","type":"symbolChange","dateTimestamp":1518411600000},{"market":"US","date":"2017-11-09","symbol":"WAC","fiscalQuarterEnding":"2017/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1510203600000,"reportTimeType":"","actualEps":-0.88},{"market":"US","date":"2017-08-09","symbol":"WAC","fiscalQuarterEnding":"2017/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1502251200000,"reportTimeType":"","actualEps":-0.35},{"market":"US","date":"2017-05-10","symbol":"WAC","fiscalQuarterEnding":"2017/03","expectedEps":-0.98,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1494388800000,"reportTimeType":"pre","actualEps":-0.71},{"market":"US","date":"2017-03-14","symbol":"WAC","fiscalQuarterEnding":"2016/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1489464000000,"reportTimeType":"","actualEps":-1.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"WAC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"WAC\",market:\"US\",delay:false,,,undefined,":{}}}